Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma

Launched by INSTITUT JEAN-GODINOT · Nov 28, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how a skin condition called helioderma, which is caused by sun exposure, might affect how well patients with metastatic melanoma respond to immunotherapy. Metastatic melanoma is a serious type of skin cancer that can spread to other parts of the body. Immunotherapy is a treatment that helps the immune system fight cancer, but not everyone responds to it. The researchers want to see if having helioderma could be linked to better or worse responses to this treatment.

To participate in the trial, individuals must be over 18 years old and diagnosed with metastatic melanoma, regardless of a specific mutation in their genes. They should not have started immunotherapy yet or received other treatments like chemotherapy or radiation. If you decide to join the study, you'll help researchers learn more about how sun damage might impact cancer treatment. Knowing this could lead to better care for future patients. Your participation is voluntary, and you will receive information about what being in the study entails before you agree to take part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • metastatic melanoma
• • Whatever the mutation BRAF status
• • treated by immunotherapy or specific therapy
• • aged more than 18
• • agreeing to participate to the study
• Exclusion Criteria:
• • Patient whose treatment by immunotherapy has already started
• • Patient who have had a radiotherapy or chemotherapy treatment
• • Patient with an unknown primary melanoma, choroidal melanoma
• • Patient with other cancer (except basal cell and squamous cell skin cancer)
• • Patient with genetic predisposition for melanoma
• • aged less than 18
• • Adult not agreeing to participate to the study